All News AtriCure, Inc.

Equities

ATRC

US04963C2098

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
21.89 ^USD	-2.58%		+0.09%	-38.67%

02/05	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
01/05	Earnings Flash (ATRC) ATRICURE Reports Q1 Revenue $108.9M, vs. Street Est of $106.9M	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	02/05	MT
Earnings Flash (ATRC) ATRICURE Reports Q1 Revenue $108.9M, vs. Street Est of $106.9M	02/05	MT
AtriCure: Q1 Earnings Snapshot	02/05	AQ
Transcript : AtriCure, Inc., Q1 2024 Earnings Call, May 01, 2024	02/05
AtriCure Reports First Quarter 2024 Financial Results	02/05	BU
AtriCure, Inc. Provides Earnings Guidance for the Year 2024	02/05	CI
AtriCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference	30/04	BU
Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	23/04	MT
AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management	19/04	AQ
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management	18/04	BU
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	18/04	CI
AtriCure to Announce First Quarter 2024 Financial Results	10/04	BU
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03	BU
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	07/03	MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	27/02	CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	16/02	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	16/02	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	16/02	MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	16/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News AtriCure, Inc.

Equities

ATRC

US04963C2098

All News

Filters